Mutual of America Capital Management’s ImmunityBio IBRX Stock Holding History

Mutual of America Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-117,439	Closed	-$714K	–	1640
2021 Q4	$714K	Sell	117,439 -1,096	-0.9%	-$8.23K	0.01%	1078
2021 Q3	$1.16M	Sell	118,535 -1,709	-1%	-$18.8K	0.01%	1050
2021 Q2	$1.72M	Sell	120,244 -43,176	-26%	-$713K	0.02%	1020
2021 Q1	$3.88M	Sell	163,420 -9,043	-5%	-$234K	0.04%	656
2020 Q4	$2.3M	Buy	172,463 +49,274	+40%	+$474K	0.03%	846
2020 Q3	$854K	Buy	+123,189	New	+$1.23M	0.01%	1058

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Allen Holding New York $1.01B AUM 14.43% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mutual of America Capital Management's IBRX Position: Q1 2022 in Review

Mutual of America Capital Management sold out of ImmunityBio (IBRX) in Q1 2022, closing a stake of 117,439 shares — an estimated $714K sold.

Mutual of America Capital Management first reported a position in IBRX in Q3 2020 and held it in 6 quarters. The position peaked at $3.88M in Q1 2021. 149 funds tracked by Wall St. Rank hold IBRX as of Q1 2022.

Mutual of America Capital Management reported no remaining ImmunityBio position as of Q1 2022 after selling out during the quarter.
Mutual of America Capital Management sold 117,439 ImmunityBio shares in Q1 2022, an estimated $714K.
Mutual of America Capital Management first reported a position in ImmunityBio in Q3 2020 and held it in 6 quarters.
Mutual of America Capital Management's ImmunityBio position peaked at $3.88M in Q1 2021.
149 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2022.

Based on Mutual of America Capital Management's 13F filing for Q1 2022, filed 2 May 2022.